Rational methods for the selection of diverse screening compounds

ACS Chemical Biology

Volumn 6, Issue 3, 2011, Pages 208-217

  Huggins, David J ^a,b   Venkitaraman, Ashok R ^b   Spring, David R ^b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMICAL STRUCTURE; DATA BASE; DRUG DEVELOPMENT; DRUG MANUFACTURE; DRUG SCREENING; FILTRATION; PRIORITY JOURNAL; REVIEW;

DRUG EVALUATION, PRECLINICAL; HIGH-THROUGHPUT SCREENING ASSAYS; PHARMACEUTICAL PREPARATIONS; SMALL MOLECULE LIBRARIES;

EID: 79955637690     PISSN: 15548929     EISSN: 15548937     Source Type: Journal    
DOI: 10.1021/cb100420r     Document Type: Review

References (101)

1. Pauling, L., Itano, H., Singer, S., and Wells, I. (1949) Sickle cell anemia, a molecular disease. Science 110, 543.
2. Koehn, F. E., and Carter, G. T. (2005) The evolving role of natural products in drug discovery. Nat. Rev. Drug Discovery 4, 206-220. (Pubitemid 40372555)
3. Kennedy, J. P., Williams, L., Bridges, T. M., Daniels, R. N., Weaver, D., and Lindsley, C. W. (2008) Application of combinatorial chemistry science on modern drug discovery. J. Comb. Chem. 10, 345-354.
4. Spring, D. R. (2005) Chemical genetics to chemical genomics: small molecules offer big insights. Chem. Soc. Rev. 34, 472-482. (Pubitemid 40880427)
5. Kodadek, T. (2010) Rethinking screening. Nat. Chem. Biol. 6, 162-165.
6. McCarthy, A. (2010) The NIH molecular libraries program: identifying chemical probes for new medicines. Chem. Biol. 17, 549-550.
7. Workman, P., and Collins, I. (2010) Probing the probes: fitness factors for small molecule tools. Chem. Biol. 17, 561-577.
8. Inglese, J., Johnson, R. L., Simeonov, A., Xia, M. H., Zheng, W., Austin, C. P., and Auld, D. S. (2007) High-throughput screening assays for the identification of chemical probes. Nat. Chem. Biol. 3, 466-479. (Pubitemid 47080373)
9. Brenk, R., Schipani, A., James, D., Krasowski, A., Gilbert, I. H., Frearson, J., and Wyatt, P. G. (2008) Lessons learnt from assembling screening libraries for drug discovery for neglected diseases. ChemMed- Chem 3, 435-444.
10. Ajay, Walters, W. P., and Murcko, M. A. (1998) Can we learn to distinguish between "drug-like" and "nondrug-like" molecules?. J. Med. Chem. 41, 3314-3324. (Pubitemid 28406538)
11. Teague, S. J., Davis, A. M., Leeson, P. D., and Oprea, T. (1999) The design of leadlike combinatorial libraries. Angew. Chem., Int. Ed. 38, 3743-3748. (Pubitemid 30022004)
12. Lloyd, D. G., Golfis, G., Knox, A. J., Fayne, D., Meegan, M. J., and Oprea, T. I. (2006) Oncology exploration: charting cancer medicinal chemistry space. Drug Discovery Today 11, 149-159. (Pubitemid 43375966)
13. Baurin, N., Baker, R., Richardson, C., Chen, I., Foloppe, N., Potter, A., Jordan, A., Roughley, S., Parratt, M., Greaney, P., Morley, D., and Hubbard, R. E. (2004) Drug-like annotation and duplicate analysis of a 23-supplier chemical database totalling 2.7 million compounds. J. Chem. Inf. Comput. Sci. 44, 643-651.
14. Chuprina, A., Lukin, O., Demoiseaux, R., Buzko, A., and Shivanyuk, A. (2010) Drug- and lead-likeness, target class, and molecular diversity analysis of 7.9 million commercially available organic compounds provided by 29 suppliers. J. Chem. Inf. Model. 50, 470-479.
15. Editorial (2007) The academic pursuit of screening, Nat. Chem. Biol. 3, 433-433.
16. Monge, A., Arrault, A., Marot, C., and Morin-Allory, L. (2006) Managing, profiling and analyzing a library of 2.6 million compounds gathered from 32 chemical providers. Mol Divers 10, 389-403. (Pubitemid 44546690)
17. Sirois, S., Hatzakis, G., Wei, D. Q., Du, Q. S., and Chou, K. C. (2005) Assessment of chemical libraries for their druggability. Computational Biology and Chemistry 29, 55-67. (Pubitemid 40146367)
18. Verheij, H. J. (2006) Leadlikeness and structural diversity of synthetic screening libraries. Mol. Diversity 10, 377-388. (Pubitemid 44546689)
19. Voigt, J. H., Bienfait, B., Wang, S. M., and Nicklaus, M. C. (2001) Comparison of the NCI open database with seven large chemical structural databases. J. Chem. Inf. Comput. Sci. 41, 702-712.
20. Irwin, J. J., and Shoichet, B. K. (2005) ZINC-a free database of commercially available compounds for virtual screening. J. Chem. Inf. Model. 45, 177-182. (Pubitemid 40736970)
21. Bohacek, R. S., McMartin, C., and Guida, W. C. (1996) The art and practice of structure-based drug design: a molecular modeling perspective. Med. Res. Rev. 16, 3-50. (Pubitemid 26037075)
22. Fink, T., and Reymond, J. L. (2007) Virtual exploration of the chemical universe up to 11 atoms of C, N, O, F: assembly of 26.4 million structures (110.9 million stereoisomers) and analysis for new ring systems, stereochemistry, physicochemical properties, compound classes, and drug discovery. J. Chem. Inf. Model. 47, 342-353. (Pubitemid 46615939)
23. Higueruelo, A. P., Schreyer, A., Bickerton, G. R. J., Pitt, W. R., Groom, C. R., and Blundell, T. L. (2009) Atomic interactions and profile of small molecules disrupting protein-protein interfaces: the TIMBAL database. Chem. Biol. Drug Des. 74, 457-467.
24. Lovering, F., Bikker, J., and Humblet, C. (2009) Escape from flatland: increasing saturation as an approach to improving clinical success. J. Med. Chem. 52, 6752-6756.
25. Ritchie, T. J., and Macdonald, S. J. (2009) The impact of aromatic ring count on compound developability-are too many aromatic rings a liability in drug design?. Drug Discovery Today 14, 1011-1020.
26. Newman, D. J., and Cragg, G. M. (2007) Natural products as sources of new drugs over the last 25 years. J. Nat. Prod. 70, 461-477. (Pubitemid 46595760)
27. Singh, N., Guha, R., Giulianotti, M. A., Pinilla, C., Houghten, R. A., and Medina-Franco, J. L. (2009) Chemoinformatic analysis of combinatorial libraries, drugs, natural products, and molecular libraries small molecule repository. J. Chem. Inf. Model. 49, 1010-1024.
28. Feher, M., and Schmidt, J. M. (2003) Property distributions: differences between drugs, natural products, and molecules from combinatorial chemistry. J. Chem. Inf. Comput. Sci. 43, 218-227.
29. Hert, J., Irwin, J. J., Laggner, C., Keiser, M. J., and Shoichet, B. K. (2009) Quantifying biogenic bias in screening libraries. Nat. Chem. Biol. 5, 479-483.
30. Spandl, R. J., Bender, A., and Spring, D. R. (2008) Diversityoriented synthesis; a spectrum of approaches and results. Org. Biomol. Chem. 6, 1149-1158. (Pubitemid 351432832)
31. Clemons, P. A., Bodycombe, N. E., Carrinski, H. A., Wilson, J. A., Shamji, A. F., Wagner, B. K., Koehler, A. N., and Schreiber, S. L. (2010) Small molecules of different origins have distinct distributions of structural complexity that correlate with protein-binding profiles. Proc. Natl. Acad. Sci. U.S.A. 107, 18787-18792.
32. Hann, M. M., Leach, A. R., and Harper, G. (2001) Molecular complexity and its impact on the probability of finding leads for drug discovery. J. Chem. Inf. Comput. Sci. 41, 856-864.
33. Dobson, P. D., and Kell, D. B. (2008) Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule?. Nat. Rev. Drug Discovery 7, 205-220. (Pubitemid 351321232)
34. Lipinski, C. A., Lombardo, F., Dominy, B. W., and Feeney, P. J. (1997) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev. 23, 3-25. (Pubitemid 27046991)
35. Ghose, A. K., Viswanadhan, V. N., and Wendoloski, J. J. (1999) A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases. J. Comb. Chem. 1, 55-68.
36. Veber, D. F. (2003) Molecular properties that influence the oral bioavailability of drug candidates. Abstr. Papers Am. Chem. Soc. 225, U208-U208.
37. Walters, W. P., and Murcko, M. A. (2000) Library filtering systems and prediction of drug-like properties, in Virtual Screening for Bioactive Molecules (Methods and Principles in Medicinal Chemistry), pp 15-30, Wiley-VCH, Weinheim.
38. Oprea, T. I. (2000) Property distribution of drug-related chemical databases. J. Comput.-Aided Mol. Des. 14, 251-264. (Pubitemid 30175944)
39. Egan, W. J., Merz, K. M., and Baldwin, J. J. (2000) Prediction of drug absorption using multivariate statistics. J. Med. Chem. 43, 3867-3877.
40. Lee, M. L., and Schneider, G. (2001) Scaffold architecture and pharmacophoric properties of natural products and trade drugs: application in the design of natural product-based combinatorial libraries. J. Comb. Chem. 3, 284-289. (Pubitemid 33616450)
41. Martin, Y. C. (2005) A bioavailability score. J. Med. Chem. 48, 3164-3170. (Pubitemid 40628036)
42. Palm, K., Stenberg, P., Luthman, K., and Artursson, P. (1997) Polar molecular surface properties predict the intestinal absorption of drugs in humans. Pharm. Res. 14, 568-571. (Pubitemid 27220272)
43. Subramanian, G., and Kitchen, D. B. (2006) Computational approaches for modeling human intestinal absorption and permeability. J. Mol. Model. 12, 577-589. (Pubitemid 44123040)
44. Johnson, T. W., Dress, K. R., and Edwards, M. (2009) Using the Golden Triangle to optimize clearance and oral absorption. Bioorg. Med. Chem. Lett. 19, 5560-5564.
45. Leeson, P. D., and Springthorpe, B. (2007) The influence of drug-like concepts on decision-making in medicinal chemistry. Nat. Rev. Drug Discovery 6, 881-890. (Pubitemid 350042396)
46. Hughes, J. D., Blagg, J., Price, D. A., Bailey, S., DeCrescenzo, G. A., Devraj, R. V., Ellsworth, E., Fobian, Y. M., Gibbs, M. E., Gilles, R. W., Greene, N., Huang, E., Krieger-Burke, T., Loesel, J., Wager, T., Whiteley, L., and Zhang, Y. (2008) Physiochemical drug properties associated with in vivo toxicological outcomes. Bioorg. Med. Chem. Lett. 18, 4872-4875.
47. Cronin, D., and Mark, T. (2006) The role of hydrophobicity in toxicity prediction. Curr. Comput.-Aided Drug Des. 2, 405-413.
48. Wenlock, M. C., Austin, R. P., Barton, P., Davis, A. M., and Leeson, P. D. (2003) A comparison of physiochemical property profiles of development and marketed oral drugs. J. Med. Chem. 46, 1250-1256. (Pubitemid 36428230)
49. Delaney, J. S. (2005) Predicting aqueous solubility from structure. Drug Discovery Today 10, 289-295. (Pubitemid 40222221)
50. Walters, W. P., Stahl, M. T., and Murcko, M. A. (1998) Virtual screening-an overview. Drug Discovery Today 3, 160-178.
51. Weininger, D. (1988) Smiles, a chemical language and information- system 0.1. Introduction to methodology and encoding rules. J. Chem. Inf. Comput. Sci. 28, 31-36. (Pubitemid 18574254)
52. Rishton, G. M. (1997) Reactive compounds and in vitro false positives in HTS. Drug Discovery Today 2, 382-384. (Pubitemid 27368216)
53. Wishart, D. S., Knox, C., Guo, A. C., Shrivastava, S., Hassanali, M., Stothard, P., Chang, Z., and Woolsey, J. (2006) DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res. 34, D668-D672.
54. Baell, J. B., and Holloway, G. A. (2010) New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays. J. Med. Chem. 53, 2719-2740.
55. Editorial. (2009) Screening we can believe, Nat. Chem. Biol. 5, 127-127.
56. Snodin, D. J. (2010) Genotoxic impurities: from structural alerts to qualification. Org. Process Res. Dev. 14, 960-976.
57. Hopkins, A. L., Groom, C. R., and Alex, A. (2004) Ligand efficiency: a useful metric for lead selection. Drug Discovery Today 9, 430-431. (Pubitemid 38510559)
58. Hajduk, P. J., and Greer, J. (2007) A decade of fragment-based drug design: strategic advances and lessons learned. Nat. Rev. Drug Discovery 6, 211-219. (Pubitemid 46344625)
59. Miller, J. L. (2006) Recent developments in focused library design: targeting gene-families. Curr. Top. Med. Chem. 6, 19-29.
60. Thorne, N., Auld, D. S., and Inglese, J. (2010) Apparent activity in high-throughput screening: origins of compound-dependent assay interference. Curr. Opin. Chem. Biol. 14, 315-324.
61. Seidler, J., McGovern, S. L., Doman, T. N., and Shoichet, B. K. (2003) Identification and prediction of promiscuous aggregating inhibitors among known drugs. J. Med. Chem. 46, 4477-4486. (Pubitemid 37238749)
62. Feng, B. Y., Simeonov, A., Jadhav, A., Babaoglu, K., Inglese, J., Shoichet, B. K., and Austin, C. P. (2007) A high-throughput screen for aggregation-based inhibition in a large compound library. J. Med. Chem. 50, 2385-2390. (Pubitemid 46799249)
63. Huth, J. R., Mendoza, R., Olejniczak, E. T., Johnson, R. W., Cothron, D. A., Liu, Y. Y., Lerner, C. G., Chen, J., and Hajduk, P. J. (2005) ALARM NMR: a rapid and robust experimental method to detect reactive false positives in biochemical screens. J. Am. Chem. Soc. 127, 217-224. (Pubitemid 40094385)
64. Simeonov, A., Jadhav, A., Thomas, C. J., Wang, Y., Huang, R., Southall, N. T., Shinn, P., Smith, J., Austin, C. P., Auld, D. S., and Inglese, J. (2008) Fluorescence spectroscopic profiling of compound libraries. J. Med. Chem. 51, 2363-2371. (Pubitemid 351628498)
65. Pearce, B. C., Sofia, M. J., Good, A. C., Drexler, D. M., and Stock, D. A. (2006) An empirical process for the design of highthroughput screening deck filters. J. Chem. Inf. Model. 46, 1060-1068. (Pubitemid 43999150)
66. Jadhav, A., Ferreira, R. S., Klumpp, C., Mott, B. T., Austin, C. P., Inglese, J., Thomas, C. J., Maloney, D. J., Shoichet, B. K., and Simeonov, A. (2009) Quantitative analyses of aggregation, autofluorescence, and reactivity artifacts in a screen for inhibitors of a thiol protease. J. Med. Chem. 53, 37-51.
67. Axerio-Cilies, P., Castaneda, I. P., Mirza, A., and Reynisson, J. (2009) Investigation of the incidence of "undesirable" molecular moieties for high-throughput screening compound libraries in marketed drug compounds. Eur. J. Med. Chem. 44, 1128-1134.
68. Babaoglu, K., Simeonov, A., Lrwin, J. J., Nelson, M. E., Feng, B., Thomas, C. J., Cancian, L., Costi, M. P., Maltby, D. A., Jadhav, A., Inglese, J., Austin, C. P., and Shoichet, B. K. (2008) Comprehensive mechanistic analysis of hits from high-throughput and docking screens against beta-lactamase. J. Med. Chem. 51, 2502-2511. (Pubitemid 351628511)
69. Park, C. M., Bruncko, M., Adickes, J., Bauch, J., Ding, H., Kunzer, A., Marsh, K. C., Nimmer, P., Shoemaker, A. R., Song, X., Tahir, S. K., Tse, C., Wang, X. L., Wendt, M. D., Yang, X. F., Zhang, H. C., Fesik, S. W., Rosenberg, S. H., and Elmore, S. W. (2008) Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins. J. Med. Chem. 51, 6902-6915.
70. Zhang, Q., and Muegge, I. (2006) Scaffold hopping through virtual screening using 2D and 3D similarity descriptors: ranking, voting, and consensus scoring. J. Med. Chem. 49, 1536-1548. (Pubitemid 43376501)
71. Misra, R. N., Xiao, H. Y., Kim, K. S., Lu, S. F., Han, W. C., Barbosa, S. A., Hunt, J. T., Rawlins, D. B., Shan, W. F., Ahmed, S. Z., Qian, L. G., Chen, B. C., Zhao, R. L., Bednarz, M. S., Kellar, K. A., Mulheron, J. G., Batorsky, R., Roongta, U., Kamath, A., Marathe, P., Ranadive, S. A., Sack, J. S., Tokarski, J. S., Pavletich, N. P., Lee, F. Y. F., Webster, K. R., and Kimball, S. D. (2004) N-(Cycloalkylamino)acyl-2- aminothiazole inhibitors of cyclin-dependent kinase 2. N-[5-[[[5-(1,1- dimethylethyl)-2-oxazolyl]methyl] thio]-2-thiazolyl]-4-piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent. J. Med. Chem. 47, 1719-1728. (Pubitemid 38380915)
72. Pak, D. T., and Sheng, M. (2003) Targeted protein degradation and synapse remodeling by an inducible protein kinase. Science 302, 1368-1373. (Pubitemid 37452173)
73. Syed, N., Smith, P., Sullivan, A., Spender, L. C., Dyer, M., Karran, L., O'Nions, J., Allday, M., Hoffmann, I., Crawford, D., Griffin, B., Farrell, P. J., and Crook, T. (2006) Transcriptional silencing of Pololike kinase 2 (SNK/PLK2) is a frequent event in B-cell malignancies. Blood 107, 250-256. (Pubitemid 43053549)
74. Inglis, K. J., Chereau, D., Brigham, E. F., Chiou, S. S., Schobel, S., Frigon, N. L., Yu, M., Caccavello, R. J., Nelson, S., Motter, R., Wright, S., Chian, D., Santiago, P., Soriano, F., Ramos, C., Powell, K., Goldstein, J. M., Babcock, M., Yednock, T., Bard, F., Basi, G. S., Sham, H., Chilcote, T. J., McConlogue, L., Griswold-Prenner, I., and Anderson, J. P. (2009) Polo-like kinase 2 (PLK2) phosphorylates alpha-synuclein at serine 129 in central nervous system. J. Biol. Chem. 284, 2598-2602.
75. de Carcer, G., Perez de Castro, I., and Malumbres, M. (2007) Targeting cell cycle kinases for cancer therapy. Curr. Med. Chem. 14, 969-985. (Pubitemid 46672634)
76. Stein, R. L. (2003) High-throughput screening in academia: the Harvard experience. J. Biomol. Screening 8, 615-619. (Pubitemid 40514438)
77. Austin, C. P., Brady, L. S., Insel, T. R., and Collins, F. S. (2004) NIH Molecular Libraries Initiative. Science 306, 1138-1139. (Pubitemid 39488980)
78. Keseru, G. M., and Makara, G. M. (2009) The influence of lead discovery strategies on the properties of drug candidates. Nat. Rev. Drug Discovery 8, 203-212.
79. Matter, H. (1997) Selecting optimally diverse compounds from structure databases: a validation study of two-dimensional and threedimensional molecular descriptors. J. Med. Chem. 40, 1219-1229. (Pubitemid 27175101)
80. Martin, Y. C., Kofron, J. L., and Traphagen, L. M. (2002) Do structurally similar molecules have similar biological activity?. J. Med. Chem. 45, 4350-4358. (Pubitemid 35025581)
81. Rishton, G. M. (2008) Molecular diversity in the context of leadlikeness: compound properties that enable effective biochemical screening. Curr. Opin. Chem. Biol. 12, 340-351.
82. Bender, A., and Glen, R. C. (2004) Molecular similarity: a key technique in molecular informatics. Org. Biomol. Chem. 2, 3204-3218.
83. Willett, P., Barnard, J. M., and Downs, G. M. (1998) Chemical similarity searching. J. Chem. Inf. Comput. Sci. 38, 983-996. (Pubitemid 128591261)
84. Malumbres, M., and Barbacid, M. (2007) Cell cycle kinases in cancer. Curr. Opin. Genet. Dev. 17, 60-65. (Pubitemid 46109297)
85. Sybyl, Tripos, St. Louis, MO.
86. Hert, J., Willett, P., and Wilton, D. J. (2004) Comparison of fingerprint-based methods for virtual screening using multiple bioactive reference structures. J. Chem. Inf. Comput. Sci. 44, 1177-1185.
87. Naylor, E., Arredouani, A., Vasudevan, S. R., Lewis, A. M., Parkesh, R., Mizote, A., Rosen, D., Thomas, J. M., Izumi, M., Ganesan, A., Galione, A., and Churchill, G. C. (2009) Identification of a chemical probe for NAADP by virtual screening. Nat. Chem. Biol. 5, 220-226.
88. Duan, J. X., Dixon, S. L., Lowrie, J. F., and Sherman, W. (2010) Analysis and comparison of 2D fingerprints: insights into database screening performance using eight fingerprint methods. J. Mol. Graphics Model. 29, 157-170.
89. Bender, A., Jenkins, J. L., Scheiber, J., Sukuru, S. C. K., Glick, M., and Davies, J. W. (2009) How similar are similarity searching methods? A principal component analysis of molecular descriptor space. J. Chem. Inf. Modell. 49, 108-119.
90. Steffen, A., Kogej, T., Tyrchan, C., and Engkvist, O. (2009) Comparison of molecular fingerprint methods on the basis of biological profile data. J. Chem. Inf. Model. 49, 338-347.
91. Willett, P. (2006) Similarity-based virtual screening using 2D fingerprints. Drug Discovery Today 11, 1046-1053. (Pubitemid 44792477)
92. Hawkins, P. C. D., Skillman, A. G., and Nicholls, A. (2007) Comparison of shape-matching and docking as virtual screening tools. J. Med. Chem. 50, 74-82. (Pubitemid 46105500)
93. Willett, P. (1999) Dissimilarity-based algorithms for selecting structurally diverse sets of compounds. J. Comput. Biol. 6, 447-457.
94. Higgs, R. E., Bemis, K. G., Watson, I. A., and Wikel, J. H. (1997) Experimental designs for selecting molecules from large chemical databases. J. Chem. Inf. Comput. Sci. 37, 861-870. (Pubitemid 127572852)
95. Hudson, B. D., Hyde, R. M., Rahr, E., and Wood, J. (1996) Parameter based methods for compound selection from chemical databases. Quant. Struct.-Act. Relat. 15, 285-289. (Pubitemid 26283514)
96. Gobbi, A., and Lee, M. L. (2003) DISE: Directed Sphere Exclusion. J. Chem. Inf. Comput. Sci. 43, 317-323.
97. Schmuker, M., Givehchi, A., and Schneider, G. (2004) Impact of different software implementations on the performance of the Maxmin method for diverse subset selection. Mol. Diversity 8, 421-425. (Pubitemid 39491377)
98. Shoichet, B. K., McGovern, S. L., Wei, B. Q., and Irwin, J. J. (2002) Lead discovery using molecular docking. Curr. Opin. Chem. Biol. 6, 439-446. (Pubitemid 34808727)
99. Wolber, G., and Langer, T. (2005) LigandScout: 3-d pharmacophores derived from protein-bound Ligands and their use as virtual screening filters. J. Chem. Inf. Model. 45, 160-169. (Pubitemid 40736968)
100. Lipkin, M. J., Stevens, A. P., Livingstone, D. J., and Harris, C. J. (2008) How large does a compound screening collection need to be?. Comb. Chem. High Throughput Screening 11, 482-493. (Pubitemid 351969365)
101. Harper, G., Pickett, S. D., and Green, D. V. (2004) Design of a compound screening collection for use in high throughput screening. Comb. Chem. High Throughput Screening 7, 63-70. (Pubitemid 38332576)